Diffuse astrocytic tumours lacking the histological features of glioblastoma are designated molecular GBM (molGBM, WHO grade 4) if they exhibit specific molecular abnormalities, such as TERT promoter mutation, EGFR amplification, or chromosomal + 7/− 10 copy changes. This evidence concerns the gene EGFR and glioblastoma.